Usage Examples
- The drug substance CQA list and the rationale for each designation went into 3.2.S.2.6.
- Particle size distribution is a CQA here because it drives dissolution in the finished tablet.
- We reclassified the new degradant as a CQA once the risk assessment showed a safety impact.
What is Critical Quality Attribute (CQA)?
A Critical Quality Attribute is a physical, chemical, biological, or microbiological property of a drug substance, excipient, intermediate, or drug product that must be held within a defined limit, range, or distribution because its variation would compromise product quality.
Critical Quality Attributes exist because quality cannot be tested into a finished product. ICH Q8(R2) makes that point directly: quality has to be built in by design, which forces a development team to name up front the specific measurable properties that decide whether a batch is fit for a patient. A Critical Quality Attribute is that named property, so development, controls, and review all have a defined target.
A Critical Quality Attribute covers physical, chemical, biological, and microbiological properties of the drug substance, excipients, intermediates, and the drug product: purity, strength, drug release, stability, sterility for parenterals, aerodynamic performance for inhaled products. A Critical Quality Attribute is never a process parameter, never an equipment setting, and never an attribute whose variation has no demonstrated impact on the quality of the product.
A Critical Quality Attribute is established in practice through an iterative loop: derive candidates from the quality target product profile and prior knowledge, prioritise them with quality risk management, then run experiments that measure how far each attribute's variation moves product quality. The surviving list, with a written rationale for every designation, goes into 3.2.S.2.6 and drives both the control strategy and the specification justification.
Not to be confused with
- Critical Process Parameter (CPP)
- a CPP is a process input whose variability has an impact on a CQA and is therefore monitored or controlled. The CQA is the product property being protected; adjusting a CPP moves a CQA, and the dependency never runs the other way.
- Quality Target Product Profile (QTPP)
- the QTPP is the prospective summary of what the product must achieve (route of administration, dosage form, strength, release, stability). CQAs are the measurable properties derived from the QTPP, each carrying a limit, range, or distribution.
- Control strategy
- the control strategy is the planned set of controls that keeps CQAs inside their limits. The CQA is the target; the control strategy is the mechanism, and it can hold a CQA through upstream in-process control rather than end-product testing.
- Specification
- a specification is the list of tests and acceptance criteria applied at release. Criticality is a risk judgement made during development, so a CQA can be controlled without appearing as a release test, and a release test does not by itself make an attribute critical.
CQA obligations sit in the ICH quality guidelines, with the enforceable US anchor in the CGMP laboratory-controls rule.
What you must do
- 1Derive the list of potential drug product CQAs from the quality target product profile and prior knowledge, then confirm the relevant ones through an iterative process of quality risk management and experimentation that assesses how far each attribute's variation affects product qualityICH Q8(R2) Part II, Section 2.2
- 2Perform the risk assessment early in pharmaceutical development and repeat it as more information becomes available, to identify which material attributes and process parameters have an effect on product CQAsICH Q8(R2) Part II, Section 2.3
- 3Determine drug substance CQAs across identity, purity, biological activity, and stability, and evaluate impurities as a class of potential CQAs: potentially mutagenic organic impurities, metal residues, and residual solvents for chemical entities; process-related and product-related impurities for biotechnological productsICH Q11, Section 3.1.4
- 4List the drug substance CQAs in the application with the rationale for designating each one, and where appropriate explain why other candidate properties were not includedICH Q11, Section 3.2.2
- 5Establish scientifically sound and appropriate specifications, standards, sampling plans, and test procedures so that components, in-process materials, and drug products conform to appropriate standards of identity, strength, quality, and purity21 CFR 211.160(b)
Common mistakes
Designating every measured attribute as critical
Each designation owes a documented rationale in the application and pulls that attribute into the specification, method validation, stability programme, and post-approval change control for the life of the product. An inflated list buries the few attributes that actually carry patient risk and turns routine process improvement into a supplement.
Freezing the CQA list at filing
ICH Q8(R2) treats the list of potential CQAs as something that changes when the formulation and manufacturing process are selected and as process understanding increases, and ICH Q11 states that understanding of drug substance CQAs evolves during development. A process change, a new impurity, or a scale-up left un-reassessed leaves the control strategy defending the wrong attributes.
Confusing criticality with controllability
An attribute does not stop being critical because recent batches sit comfortably inside the limit. Criticality is set by the impact of variation on quality, not by current process capability, so removing a well-controlled attribute from the CQA list deletes the justification for the control that was keeping it there.
When This Matters
- The drug substance CQA list and the rationale for each designation went into 3.2.S.2.6.
- Particle size distribution is a CQA here because it drives dissolution in the finished tablet.
- We reclassified the new degradant as a CQA once the risk assessment showed a safety impact.
Frequently Asked Questions
A CPP is a process input; a CQA is a product property. ICH Q8(R2) defines a critical process parameter as one whose variability has an impact on a critical quality attribute and therefore should be monitored or controlled. Changing a CPP moves a CQA; the dependency only runs in that direction.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
